These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 36503429)

  • 1. SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?
    Rans K; Charlien B; Filip A; Olivier H; Julie DH; Céderic D; Herlinde D; Benedikt E; Karolien G; Annouschka L; Nick L; Kenneth P; Carl S; Koen S; Hans V; Ben V; Steven J; Gert M
    BMC Cancer; 2022 Dec; 22(1):1294. PubMed ID: 36503429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial.
    De Bruycker A; Spiessens A; Dirix P; Koutsouvelis N; Semac I; Liefhooghe N; Gomez-Iturriaga A; Everaerts W; Otte F; Papachristofilou A; Scorsetti M; Shelan M; Siva S; Ameye F; Guckenberger M; Heikkilä R; Putora PM; Zapatero A; Conde-Moreno A; Couñago F; Vanhoutte F; Goetghebeur E; Reynders D; Zilli T; Ost P
    BMC Cancer; 2020 May; 20(1):406. PubMed ID: 32398040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation.
    Kroeze SGC; Henkenberens C; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Christiansen H; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M
    Eur Urol Focus; 2021 Mar; 7(2):309-316. PubMed ID: 31495759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.
    Ost P; Reynders D; Decaestecker K; Fonteyne V; Lumen N; De Bruycker A; Lambert B; Delrue L; Bultijnck R; Claeys T; Goetghebeur E; Villeirs G; De Man K; Ameye F; Billiet I; Joniau S; Vanhaverbeke F; De Meerleer G
    J Clin Oncol; 2018 Feb; 36(5):446-453. PubMed ID: 29240541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of Recurrence After Metastasis-directed Therapy in Oligorecurrent Prostate Cancer Following Radical Prostatectomy.
    Milenkovic U; Kuijk J; Roussel E; Devos G; Van den Broeck T; Van Eecke H; Vanderstichele A; Duvillier T; Verhamme L; Van Haute W; Goeman L; Berghen C; Joniau S; De Meerleer G
    Eur Urol Oncol; 2023 Dec; 6(6):582-589. PubMed ID: 36878753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LUNAR: a randomized Phase 2 study of
    Ma TM; Czernin J; Felix C; Alano R; Wilhalme H; Valle L; Steinberg ML; Dahlbom M; Reiter RE; Rettig MB; Cao M; Calais J; Kishan AU
    BJU Int; 2023 Jul; 132(1):65-74. PubMed ID: 36797449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial.
    Decaestecker K; De Meerleer G; Ameye F; Fonteyne V; Lambert B; Joniau S; Delrue L; Billiet I; Duthoy W; Junius S; Huysse W; Lumen N; Ost P
    BMC Cancer; 2014 Sep; 14():671. PubMed ID: 25223986
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Zuur LG; de Barros HA; van Oosterom MN; Berrens AC; Donswijk ML; Hendrikx JJMA; Bekers EM; Vis AN; Wit EM; van Leeuwen FB; van der Poel HG; van Leeuwen PJ
    BJU Int; 2024 Jul; 134(1):81-88. PubMed ID: 38346924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy.
    Devos G; Berghen C; Van Eecke H; Stichele AV; Van Poppel H; Goffin K; Mai C; De Wever L; Albersen M; Everaerts W; De Meerleer G; Joniau S
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32823690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastasis-directed Therapy (SBRT) Guided by PET-CT
    Mazzola R; Francolini G; Triggiani L; Napoli G; Cuccia F; Nicosia L; Livi L; Magrini SM; Salgarello M; Alongi F
    Clin Genitourin Cancer; 2021 Jun; 19(3):230-236. PubMed ID: 32863189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended Results and Independent Validation of a Phase 2 Trial of Metastasis-Directed Therapy for Molecularly Defined Oligometastatic Prostate Cancer.
    Glicksman RM; Ramotar M; Metser U; Chung PW; Liu Z; Vines D; Finelli A; Hamilton R; Fleshner NE; Perlis N; Zlotta AR; Bayley A; Helou J; Raman S; Kulkarni G; Catton C; Lam T; Chan R; Warde P; Gospodarowicz M; Jaffray DA; Berlin A
    Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):693-704. PubMed ID: 36031465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.
    Privé BM; Janssen MJR; van Oort IM; Muselaers CHJ; Jonker MA; de Groot M; Mehra N; Verzijlbergen JF; Scheenen TWJ; Zámecnik P; Barentsz JO; Gotthardt M; Noordzij W; Vogel WV; Bergman AM; van der Poel HG; Vis AN; Oprea-Lager DE; Gerritsen WR; Witjes JA; Nagarajah J
    BMC Cancer; 2020 Sep; 20(1):884. PubMed ID: 32928177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy (ADOPT): study protocol for a randomised phase III trial.
    Janssen J; Staal FHE; Brouwer CL; Langendijk JA; de Jong IJ; van Moorselaar RJA; Schuit E; Verzijlbergen JF; Smeenk RJ; Aluwini S
    BMC Cancer; 2022 May; 22(1):482. PubMed ID: 35501744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PSMA-PET Guided Treatment in Prostate Cancer Patients with Oligorecurrent Progression after Previous Salvage Treatment.
    Bianchi L; Ceci F; Balestrazzi E; Costa F; Droghetti M; Piazza P; Pissavini A; Presutti M; Farolfi A; Mei R; Castellucci P; Gandaglia G; Larcher A; Robesti D; Mottrie A; Briganti A; Morganti AG; Fanti S; Montorsi F; Schiavina R; Brunocilla E
    Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial.
    Ost P; Siva S; Brabrand S; Dirix P; Liefhooghe N; Otte FX; Gomez-Iturriaga A; Everaerts W; Shelan M; Conde-Moreno A; López Campos F; Papachristofilou A; Guckenberger M; Scorsetti M; Zapatero A; Villafranca Iturre AE; Eito C; Couñago F; Muto P; Van De Voorde L; Mach N; Bultijnck R; Fonteyne V; Moon D; Thon K; Mercier C; Achard V; Stellamans K; Goetghebeur E; Reynders D; Zilli T
    Eur Urol Oncol; 2024 Jun; 7(3):462-468. PubMed ID: 37821242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage radiotherapy in patients affected by oligorecurrent pelvic nodal prostate cancer.
    Ingrosso G; Mariucci C; Tenti MV; Bini V; Alì E; Saldi S; Palumbo I; Bellavita R; Aristei C
    Clin Transl Oncol; 2020 Dec; 22(12):2236-2243. PubMed ID: 32418156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance.
    Triggiani L; Mazzola R; Tomasini D; Bruni A; Alicino G; Matrone F; Bortolus R; Francolini G; Detti B; Magli A; Bonù ML; Ingrosso G; Lancia A; Trippa F; Maranzano E; Franzese C; Ghirardelli P; Vavassori V; Scorsetti M; Alongi F; Magrini SM
    Med Oncol; 2021 May; 38(6):72. PubMed ID: 34008151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic body radiotherapy (SBRT) versus androgen deprivation therapy (ADT) for oligometastatic prostate cancer: protocol for a prospective randomised control clinical trial.
    Zhao X; Wang T; Ye Y; Li J; Gao X; Zhang H
    BMJ Open; 2022 Sep; 12(9):e051371. PubMed ID: 36180115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.
    Onal C; Kose F; Ozyigit G; Aksoy S; Oymak E; Muallaoglu S; Guler OC; Tilki B; Hurmuz P; Akyol F
    Prostate; 2021 Jun; 81(9):543-552. PubMed ID: 33905131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Risk Classification for Biochemical Relapse-Free Survival in Oligometastatic Recurrent Prostate Cancer Determined by Choline PET.
    Gravis G; Autret A; Guibert-Broudic M; Dubergé T; Zemmour C; Carrier P; Salem N; Badinand D; Cartier L; Gross E; Walz J; Pignot G; Brenot-Rossi I
    Clin Genitourin Cancer; 2021 Aug; 19(4):346-353. PubMed ID: 33849812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.